Loading

Junevity

June 16, 2025
Company Presentation
Regenerative Medicine
Junevity is a longevity biotechnology company developing Cell Reset therapeutics, a new class of medicines reversing transcriptional damage with siRNA. Junevity’s RESET platform is the first to use large-scale human data and AI to identify novel transcription factor targets for down regulation. Launched from UCSF in 2023, Junevity’s long-term goal is to bring Cell Reset therapeutics to the world for longer lifespan and healthspan.
Junevity
Company HQ City: San Francisco
Company HQ State: CA
Company HQ Country: United States
Year Founded: 2023
Lead Product in Development: siRNA for Type 2 diabetes and obesity

CEO

John Hoekman, PhD

Year Founded

2023

Development Phase of Lead Product

Pre-Clinical

Number of Unlicensed Products Looking for Licensing

3

When you expect your next catalyst update?

IND

What is your next catalyst (value inflection) update?

Mar 2026

Website

www.junevity.com
Primary Speaker
John Hoekman
John Hoekman, PhD
Co-founder & CEO
Juenevity

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS